SP 0125
Alternative Names: 534; Respiratory syncytial virus vaccine - Sanofi; RSVt vaccine; SP-0125Latest Information Update: 07 May 2024
At a glance
- Originator Sanofi
- Class Attenuated vaccines; Respiratory syncytial virus vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Respiratory syncytial virus infections
Most Recent Events
- 03 May 2024 Sanofi plans a phase III CORAL trial for Respiratory syncytial virus infections (In infants, Prevention) in April 2024 (NCT06397768)
- 19 Feb 2024 Sanofi announces intention to submit an application to the regulatory body for Respiratory syncytial virus infections (In infants, Prevention) (Intranasal), in 2026 or beyond (Sanofi pipeline, February 2024)
- 08 Feb 2024 Sanofi Pasteur plans a phase III trial for Respiratory-syncytial-virus-infections (In infants, Prevention) (Intranasal) (NCT06252285)